Oxaliplatin

Catalog No.S1224 Synonyms: L-OHP

Oxaliplatin Chemical Structure

Molecular Weight(MW): 397.29

Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 11 Publications

5 Customer Reviews

  • Cleaved caspases and p-H2AX expression were detected by western blot in HCT116 cells (E) and HT29 cells (F). The cells were co-cultured with F. nucleatum or treated with CQ, and different concentrations of Oxaliplatin and 5-FU.

    Cell, 2017, 170(3):548-563.e16. Oxaliplatin purchased from Selleck.

    Intracellular ratio between reduced and oxidized glutathione of the indicated cells treated with oxaliplatin or irinotecan for 6h was measured with spectrophotometric analysis.

    Theranostics, 2018, 8(5): 1312–1326. Oxaliplatin purchased from Selleck.

  • Immunocytochemical staining of SW620 (metastatic) cells after treatment with 10 uM oxaliplatin (F) or 10 uM ginsenosides 20(S)-Rg 3 (G) and negative staining (H). Cells demonstrated differential expression of histone H4.

    J Proteomics 2014 10.1016/j.jprot.2014.10.009. Oxaliplatin purchased from Selleck.

    PDT and oxaliplatin combination treatment. A) Bar graph showing response (total volume of residual viale nodules normalized to no treatment control) to PDT treatmen (2.5 J/cm2), oxaliplatin treatment (10 μM), and PDT followed by oxaliplatin at the same doses. The dramatic enhancement, beyond the additive effect of the two modalities independently suggests there may be a synergistic interaction. B) A representative region from a culture stained with calcein AM and ethidium bromide following treatment with the PDT + oxaliplatin combination shows relatively small pockets of viable disease and many dead relative to untreated cultures.

    Optical Methods for Tumor Treatment and Detection 2013 10.1117/12.2010730. Oxaliplatin purchased from Selleck.

  •  

    Growth inhibitory effects of Oxaliplatin in human pancreatic cancer cells. MiaPaCa-2 cells were plated in triplicates into 48-well plates at a density of 10,000 cells/ml. After 24 hours, complete culture medium was changed into fresh low-serum-containing medium (1% FBS) containing DMSO (control) or indicated doses of Oxaliplatin (Selleckchem). Cell viability 72 hours after treatment was determined by AlamarBlue assay (Invitrogen) according to manufacturer's instructions. Results are expressed as percentages of control, which was arbitrarily assigned 100% viability, and represented as the mean ± standard deviation (SD) of the tripicate wells. 

    2013 Dr. Edita Aksamitiene from Thomas Jefferson University. Oxaliplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HKESC-2 NX3mWZZYS3m2b4TvfIlkcXS7IFHzd4F6 MX6w5qCUOTZywrFOwG0> MXy0POKhcA>? M1q3RWlEPTB;NT64xsDDucLiMD61JO69VQ>? M4\UUlI3PDd2Nkmz
CaES-17 NIL3cIJEgXSxdH;4bYNqfHliQYPzZZk> MoD3NQKBmzF4MNMg{txO Mn\NOFjDqGh? Mk\pTWM2OD13LkZCpOKyyqByLkKg{txO MnnFNlY1PzR4OUO=
SW480 NIrlO2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYq0PEBpyqB? NXm2Z3FtUUN3ME2xMlg4KM7:TR?= MUmyOlI3QTd3OR?=
HCT116 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfTWYQ1QCCqwrC= MVvJR|UxRTFzLki2JO69VQ>? NXG3Ulc2OjZ{Nkm3OVk>
LoVo MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnxbVhUPDhiaNMg NFH1XIpKSzVyPUm0Mlg{KM7:TR?= NFLLPYQzPjJ4OUe1PS=>
SK-BR-3 NH\QPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HLWGlEPTB;M{GuNEDDuSByLkGg{txO MY[yOlIyOTV7MR?=
MCF-7 M3TR[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTF3LkSgxtEhOC5|IN88US=> NETqZ4MzPjJzMUW5NS=>
MDA-MB-231 NVzhSohyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrWfI9KSzVyPUKzMlEhyrFiMD6xJO69VQ>? NHKxVYEzPjJzMUW5NS=>
HCT116 p53+/+ MnvuSpVv[3Srb36gRZN{[Xl? M4fy[VEwPSEQvF2= NHHlcFczPC92ODDo Mmq2bY5lfWOnczD0doFve2O{aYD0bY9v[WxicnXwdoV{e2mxbjDv[kBFXVRvTh?= NWLuSpRKOjZ{MEi1NlM>
LoVo  M2T4UmZ2dmO2aX;uJGF{e2G7 NVrwNpFLOS93IN88US=> NILS[pczPC92ODDo MkPabY5lfWOnczD0doFve2O{aYD0bY9v[WxicnXwdoV{e2mxbjDv[kBFXVRvTh?= NUfwepVxOjZ{MEi1NlM>
SNU-398 NITXO3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTZwNdMgxtHDqDFwMTFOwG0> MUOyOlE3ODR{OR?=
Hep-G2 MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF|LkJCpOKyyqBzLk[g{txO NVG1[Yp1OjZzNkC0Nlk>
SNU-475 M2\mdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLsWXR{UUN3MP-8olMxKM7:TR?= MmjFNlYyPjB2Mkm=
SNU-387 NXPYcoJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHj6Z5ZKSzVyPUK1xsDDucLiMj63JO69VQ>? Mny3NlYyPjB2Mkm=
HT29 NYfTVI1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwOElCpOKyyqByLkKg{txO NX35bFRDOjZzNEi1PVY>
HCT116 M3P5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEX6NW5KSzVyPUCuOFHDqMLzwrCwMlAzKM7:TR?= NEC5UIEzPjF2OEW5Oi=>
PA-1 NHv1[odE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGrm[WUxNTJyIN88US=> MWWyOE81QCCq NGTwcVNqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NUPtVZRiOjZzM{i2O|E>
OVCAR-5 NWD3bppUS2WubDDWbYFjcWyrdImgRZN{[Xl? NWHORoI3OC14MDFOwG0> NV;oT4tvOjRxNEivO|IhcA>? MXvpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NXTTd5Z3OjZzM{i2O|E>
SK-OV-3 NIm4XZpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3\RblAuOTByIN88US=> NHzT[GUzPC92OD:3NkBp NVLTdGF1cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NVPMbnpuOjZzM{i2O|E>
PA-1 NGHkS4JHfW6ldHnvckBCe3OjeR?= MV6xNEDPxE4EoB?= NXLIN4NMOjSq M{T0fpRzcWepZYLld{B1cGVicILv[JVkfGmxbjDv[kB1gXCnIFmgTWZPeyCjbnSgZ4hmdW:taX7ldy=> MlLpNlYyOzh4N{G=
OVCAR-5 M1rCOWZ2dmO2aX;uJGF{e2G7 M3yzTlMxKM7:TR?= MmLxOFhp M3f1TJRzcWepZYLld{B1cGVicILv[JVkfGmxbjDv[kB1gXCnIFmgTWZPeyCjbnSgZ4hmdW:taX7ldy=> NVHC[lhZOjZzM{i2O|E>
SK-OV-3 M{PQc2Z2dmO2aX;uJGF{e2G7 NITMbYs2OCEQvF2= NXrEeXlSQTZiaB?= NUfsNWlxfHKrZ3fldoV{KHSqZTDwdo9lfWO2aX;uJI9nKHS7cHWgTUBKTk6|IHHu[EBkcGWvb3vpcoV{ M1TaW|I3OTN6Nkex
PA-1 NIrhe5dHfW6ldHnvckBCe3OjeR?= MWSxNEDPxE4EoB?= MXq0PIg> M{jIVZVxNXKnZ4XsZZRmeyC2aHWgd5Rz\XO|IHzp[4Fv\HNiZn;yJG5MKGOnbHytZYN1cX[jdHnu[{Bz\WOncITvdpMh[W6mIGTSRWlNKHKnY3XweI9zew>? NU\ZN3BOOjZzM{i2O|E>
OVCAR-5 MWrGeY5kfGmxbjDBd5NigQ>? Ml;PN|Ah|ryP M4XUZ|Q5cA>? NFfSSYN2eC2{ZXf1cIF1\XNidHjlJJN1emW|czDsbYdidmS|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN? MUSyOlE{QDZ5MR?=
SK-OV-3 MnnzSpVv[3Srb36gRZN{[Xl? M4DHVVUxKM7:TR?= M33Ydlk3KGh? NXTyTnNofXBvcnXneYxifGW|IITo[UB{fHKnc4OgcIlo[W6mczDmc5IhVktiY3XscE1i[3SrdnH0bY5oKHKnY3XweI9zeyCjbnSgWHJCUUxicnXj[ZB1d3K| Ml[0NlYyOzh4N{G=
PA-1 MYrGeY5kfGmxbjDBd5NigQ>? MUCxNEDPxE4EoB?= MUOyOIg> NX7UeVFZeHKxbX;0[ZMhe2Wwc3n0bZZqfHlib3[gc5ZiemmjbjDjZZJkcW6xbXGgeI8hVktiY3XscE1u\WSrYYTl[EBkgXSxbInzbZM> MWqyOlE{QDZ5MR?=
OVCAR-5 M4Lk[mZ2dmO2aX;uJGF{e2G7 NYDqW4pLOjBizszNxsA> M3flV|I1cA>? MUnwdo9ud3SnczDz[Y5{cXSrdnn0fUBw\iCxdnHybYFvKGOjcnPpco9u[SC2bzDOT{Bk\WyuLX3l[IlifGWmIHP5eI9tgXOrcx?= MUmyOlE{QDZ5MR?=
SK-OV-3 NUnybWtLTnWwY4Tpc44hSXO|YYm= NWnrWGpiPTBizszNxsA> M1nBd|Q5KGkEoB?= NUfkVIZyeHKxbX;0[ZMhe2Wwc3n0bZZqfHlib3[gc5ZiemmjbjDjZZJkcW6xbXGgeI8hVktiY3XscE1u\WSrYYTl[EBkgXSxbInzbZM> MnT0NlYyOzh4N{G=
CT26  M3r3T2Z2dmO2aX;uJGF{e2G7 MVG0JI1O M4PxdVQ5KGkEoB?= NVTTNm1xcW6mdXPld{BifXSxcHjh[5k> NE\SZ28zPjF|N{CxNi=>
CT26  NXvNVXV2TnWwY4Tpc44hSXO|YYm= MV[0JI1O M1fxOFQ5KGkEoB?= Mk\ZbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVteyCxZjDheZRweGijZ4mtdoVt[XSnZDDwdo91\Wmwczygd5VkcCCjczDMR|MuUUluIFLlZ4xqdjFiYX7kJGFVTzV? NXXL[lI3OjZzM{ewNVI>
CT26  M4C4UWNmdGxiVnnhZoltcXS7IFHzd4F6 M3zV[|QhdU1? M1OxW|Q5KGkEoB?= Mk[3[IVkemWjc3XzJINmdGxidnnhZoltcXS7IITvJFU{NjJn M1rkU|I3OTN5MEGy
BE MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XvbmlEPTB;Mz6zN{DPxE1? MkXCNlYxOjNyOEW=
Colo205 M13DfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHxTWM2OD1|LkOzJO69VQ>? NY\4bXlsOjZyMkOwPFU>
DLD1 Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTuTlBIUUN3ME2yMlAyKM7:TR?= MVWyOlAzOzB6NR?=
HT29 NUDIbot{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHITWM2OD1{Lk[5JO69VQ>? NXXoSmdQOjZyMkOwPFU>
HCT15 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr4Ro9EUUN3ME2xMlQ{KM7:TR?= NFvZcIEzPjB{M{C4OS=>
HCT116 NWr4PHljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHO0TXlKSzVyPUGuNFQh|ryP MlLJNlYxOjNyOEW=
HCT116p53- M1HlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFwMEig{txO NXnPSZRHOjZyMkOwPFU>
KM12 M4nVO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfKW2dKSzVyPUSuN|ch|ryP M4jSfFI3ODJ|MEi1
LoVo NFL4NIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DCdWlEPTB;MT6yJO69VQ>? MlXtNlYxOjNyOEW=
RKO Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTGTWM2OD1zLkKzJO69VQ>? MU[yOlAzOzB6NR?=
SW480 M{nGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPPeW5KSzVyPUKuPFYh|ryP M3jPU|I3ODJ|MEi1
SW620 NHezVnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HySGlEPTB;Mz62PEDPxE1? NEfaNJUzPjB{M{C4OS=>
MC38 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjGSXBSUUN3ME2yN{DPxE1iwsGgNi=> MV6yOlAxPDB6NB?=
HT29 NEHCc|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\ETVRmUUN3ME22N{DPxE1iwsGgNVg> M1zKblI3ODB2MEi0
DLD-1 NH7IbmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\kcWU1UUN3ME2zNk4zKM7:TR?= M4XiWVI3ODB|MEi1
HT-29 NWTWW4VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi1VI5KSzVyPUO1MlYh|ryP M3\5dFI3ODB|MEi1
SiHa MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XMe2lEPTB;MD64JOKyKDBwMTFOwG0> MVmyOVgxOTByNx?=
S3 NXLEVFdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTV|LkWgxtEhOS53IN88US=> MmTFNlU5ODFyMEe=
AGS MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDX[GJKSzVyPUGwMlYh|ryP MkjENlU4QDlyNUe=
MKN-45 NGrLbWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTF2LkCg{txO MVmyOVc5QTB3Nx?=
TMK-1 M2DSd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHX5fmVKSzVyPUKyMlYh|ryP MYiyOVc5QTB3Nx?=
SCM-1 NFjhbGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPkW4FKSzVyPUG3MlUh|ryP NXLEXnRyOjV5OEmwOVc>
HCT-15 NVfpdItXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjNTWM2OD16Lk[0JO69VQ>? NVjUcmdSOjV5NkG0O|k>
DiFi MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fuXmlEPTB;MUCuPVUh|ryP MknvNlU4PjF2N{m=
DLD-1 M2nUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkSwTWM2OD16Lk[1JO69VQ>? M3fPdlI2PzZzNEe5
COLO-320DM M1fjRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTVwM{ig{txO NGXN[HozPTd4MUS3PS=>
SNU-175 NYTGOII2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1T4WmlEPTB;MT61NUDPxE1? NGjucYkzPTd4MUS3PS=>
HT-29 NUexZZZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3aTWM2OD13LkKyJO69VQ>? MWGyOVc3OTR5OR?=
SW620 MYXGeY5kfGmxbjDBd5NigQ>? MoWyNVDjiIoEtXevcYw> M3LOeVI16oDLaB?= MorobY5kemWjc3XzJGxEOy2LSTDhZ4N2dXWuYYTpc44h[W6mIHTlZ5Jm[XOnczDQOlIh\XiycnXzd4lwdg>? NWfVS5dmOjV5NEm0NlA>
SW480 MUnGeY5kfGmxbjDBd5NigQ>? NEjrPHAyOOLCidM1[{9udA>? MlnxNlTjiImq M{i3XYlv[3KnYYPld{BNSzNvSVmgZYNkfW23bHH0bY9vKGGwZDDk[YNz\WG|ZYOgVFYzKGW6cILld5Nqd25? M3ridVI2PzR7NEKw
SW620 NGPCWVhHfW6ldHnvckBCe3OjeR?= M1v6dFEx6oDLwsXnM41t MUSyOQKBkWh? MWTlcohidmOnczDj[YxtfWyjcjDheZRweGijZ3njJIZtfXh? MkT0NlU4PDl2MkC=
SW480 Mo\ySpVv[3Srb36gRZN{[Xl? MUmxNQKBkcL3Zz;tcC=> NGfnOXQzPOLCiXi= MVHlcohidmOnczDj[YxtfWyjcjDheZRweGijZ3njJIZtfXh? MmD0NlU4PDl2MkC=
A549 NXqxNmhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnnTWM2OD13LkigxtEhOC54IN88US=> NXnmXFAzOjV4MkWyOFM>
A549/CDDP NGT0bGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLqTWM2OD1zOD62JOKyKDFwMjFOwG0> MYOyOVYzPTJ2Mx?=
Panc-1 NYrNZ4o{S2WubDDWbYFjcWyrdImgRZN{[Xl? NHjrPIozPS93MDFOwG0> NVLzTYdEOjRxNEigbC=> Mn;ibY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MnTvNlU1PDR7MUS=
MIAPaCa-2 M4\BPGNmdGxiVnnhZoltcXS7IFHzd4F6 Ml;tNlUwPTBizszN NVnjOZdlOjRxNEigbC=> MXnpcohq[mm2czDwdo9tcW[ncnH0bY9vKG:oIGDDJINmdGy|IHnuJIEhe3mwZYLnbZN1cWNibXHucoVzKGOxbXLpcoVlKHerdHigW2E> MYSyOVQ1PDlzNB?=
SW1990 NVjXW3pUS2WubDDWbYFjcWyrdImgRZN{[Xl? MXGyOU82OCEQvF2= MmfCNlQwPDhiaB?= MX;pcohq[mm2czDwdo9tcW[ncnH0bY9vKG:oIGDDJINmdGy|IHnuJIEhe3mwZYLnbZN1cWNibXHucoVzKGOxbXLpcoVlKHerdHigW2E> NV20UXZiOjV2NES5NVQ>
HPDE M3TEVGNmdGxiVnnhZoltcXS7IFHzd4F6 MXiyOU82OCEQvF2= MUeyOE81QCCq MYHpcohq[mm2czDwdo9tcW[ncnH0bY9vKG:oIGDDJINmdGy|IHnuJIEhe3mwZYLnbZN1cWNibXHucoVzKGOxbXLpcoVlKHerdHigW2E> MkTGNlU1PDR7MUS=
Panc-1 M3XoOmFxd3C2b4Ppd{BCe3OjeR?= Ml\aNlXjiIoEtV2= M3XJWlI1KGh? MWnpcoR2[2W|IHHwc5B1d3OrczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MkK1NlU1PDR7MUS=
MIAPaCa-2 MlHVRZBweHSxc3nzJGF{e2G7 NEHBS2MzPeLCidM1US=> Mn7BNlQhcA>? M1rPbolv\HWlZYOgZZBweHSxc3nzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F? MlHaNlU1PDR7MUS=
Panc-1 NIHSenVHfW6ldHnvckBCe3OjeR?= NInpZVMzPeLCidM1US=> MYOyOE81QCCq M1XDdYlv\HWlZYOgZ4xm[X[jZ3Wgc4YhWEGUUDygZ4F{eGG|ZT25MEBk[XOyYYPlMVgh[W6mIHPhd5Bie2VvM9Mg MWOyOVQ1PDlzNB?=
MIAPaCa-2 NILKVXhHfW6ldHnvckBCe3OjeR?= M3u2O|I26oDLwsXN MUiyOE81QCCq M4njOIlv\HWlZYOgZ4xm[X[jZ3Wgc4YhWEGUUDygZ4F{eGG|ZT25MEBk[XOyYYPlMVgh[W6mIHPhd5Bie2VvM9Mg MV6yOVQ1PDlzNB?=
SW480 MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXYO|IhcMLi MVvJR|UxRTFyLkhCtVIvOjZiwsXnM41N Mn\1NlU{PjB4M{G=
HCT116  NYfpVGhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDMfVR[PzJiaNMg NHTZU3RKSzVyPU[uNlPDuTBwN{WgxtVoN22O NIrzbZMzPTN4ME[zNS=>
COC1 NULUNo1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7PTWM2OD12Nj6yNOKhyrIEoEOuNVQh|ryP M3HGbFI2OzB5NES4
SGC7901 MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJzLkezxsDDucLiMz6wPEDPxE1? M2PTOFI2OzB5NES4
A549 NWfiW5IzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELG[5lKSzVyPUWxMlA5yqEEsdMgNVAvQTZizszN NHzqWoMzPTNyN{S0PC=>
HepG2 NGXUPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[3NmM5UUN3ME2xOE4zPMLiwsJCpFEvQDJizszN M2DQbVI2OzB5NES4
MCF-7 NVXZNI1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXETWM2OD1zND6yOOKhyrIEoEGuPFIh|ryP NH3yeXMzPTNyN{S0PC=>
HCT-116 M{m2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj4TWM2OD14LkK0xsDDucLiMj65O{DPxE1? M1HBOVI2OzB5NES4
HT-29 NV;rUXd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLHTWM2OD53MDFOwG0> MXuyOVMxPzR2OB?=
HEK293 NGj2fXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrv[5NKSzVyPUiuPFLDqMLzwrC1MlU6KM7:TR?= M4n5[|I2OzB5NES4
HUVEC MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn36TWM2OD1zMT6zNOKhyrIEoEGuNFIh|ryP MmrJNlU{ODd2NEi=
SW480 NXOwfolIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHVNeKh|ryP M{T3blAuPzJiaB?= NVvaU5NbcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? NIX2fXAzPDl7N{S1NS=>
HT-29 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqxxsDPxE1? M17mT|AuPzJiaB?= Ml;sbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> M1r2fVI1QTl5NEWx
HCT116 MWHGeY5kfGmxbjDBd5NigQ>? NXfKNnFEOi93INM1US=> M4f6[lI1NzR6IHi= M4OyeJN2eHC{ZYPz[ZMhe3W{dnn2bY4hdVKQQTDlfJBz\XO|aX;u NGP1SIszPDd4MUSxNS=>
SW480  MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;hcFk1QCCqwrC= NWO5d41sUUN3ME2yNE45KHWpL33M MXWyOFczODZ5NR?=
SW620 NIPweY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjiUlIyOC15MDDt[{9N M3HSUFI1NzR6L{eyJIg> MlTObY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NFrHTYwzPDZ2NkOwOS=>
Caco2  M1e4PWZ2dmO2aX;uJGF{e2G7 NGPPWow{OMLizszN M2K0[VI1KGh? MXrEUXNQ MYHpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFjPMVEtKEGNUkHDMEBidmRiTmHPNS=> MnexNlQ2PTZ2MUW=
Caco2  NGj6PJJHfW6ldHnvckBCe3OjeR?= NYnYNYZROy9zMD:zNEDPxE1? NHPtTJMyPiCq NYfUR5ZOTE2VTx?= NFP0dWhqdmO{ZXHz[ZMhfGinIH3SUmEhdGW4ZXzzJI9nyqCDS2KxR|EtKE6TT{GsJGhQNTFuIF3SVFItyqCjbnTNVnA{yqCmb4PlMYRmeGWwZHXueIx6 NEP0XIUzPDV3NkSxOS=>
Caco2 M{HoUWZ2dmO2aX;uJGF{e2G7 MWKzNE8yODEEoN88US=> M{KzOlE3yqCq NIe4UlVFVVOR NVu0NYFJ[WO2aY\heIV{KE6{ZkK= M{LWT|I1PTV4NEG1

... Click to View More Cell Line Experimental Data

In vivo A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

Protocol

Cell Research:[4]
+ Expand
  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method: The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
  • Formulation: Water solution
  • Dosages: 10 mg/kg
  • Administration: A weekly i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro Water 3 mg/mL warmed (7.55 mM)
Ethanol 0.01 mg/mL (0.02 mM)
DMF Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% glucose (with warming)
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 397.29
Formula

C8H14N2O4Pt

CAS No. 61825-94-3
Storage powder
in solvent
Synonyms L-OHP

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03784326 Not yet recruiting Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Esophageal Adenocarcinoma AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 M.D. Anderson Cancer Center|National Cancer Institute (NCI) May 31 2019 Early Phase 1
NCT03784326 Not yet recruiting Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Esophageal Adenocarcinoma AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 M.D. Anderson Cancer Center|National Cancer Institute (NCI) May 31 2019 Early Phase 1
NCT03626922 Not yet recruiting Metastatic Colorectal Cancer NSABP Foundation Inc|Merck Sharp & Dohme Corp.|Eli Lilly and Company April 2019 Phase 1
NCT03626922 Not yet recruiting Metastatic Colorectal Cancer NSABP Foundation Inc|Merck Sharp & Dohme Corp.|Eli Lilly and Company April 2019 Phase 1
NCT03366155 Recruiting Colorectal Cancer|Liver Metastases|Colorectal Adenocarcinoma|Colorectal Cancer With Hepatic Metastases|Colorectal Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) March 1 2019 Phase 2
NCT03813784 Not yet recruiting Gastric Cancer|GastroEsophageal Cancer Jiangsu HengRui Medicine Co. Ltd. March 2019 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is it ok to dissolve Oxaliplatin in DMSO?

  • Answer:

    Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products0

Tags: buy Oxaliplatin | Oxaliplatin supplier | purchase Oxaliplatin | Oxaliplatin cost | Oxaliplatin manufacturer | order Oxaliplatin | Oxaliplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID